Bladder cancer: treatment after progression. Results of the second retrospective analysis of data on the efficacy of vinflunin in patients with metastatic urothelial cancer in real clinical practice in Russia

L. V. Bolotina, I. N. Zaborskiy, K. N. Safiullin, E. V. Gurin, L. N. Volodina, E. S. Semyonova, A. A. Gurchev, O. P. Gladkikh, A. S. Zhabina, A. V. Tarasova
2020 Onkourologiâ  
Objective. There is the second generalized analysis of administration of vinflunine in real clinical practice in Russia.Materials and methods. This analysis gathered 15 patients with urothelial carcinoma treated using this medicine in 8 cancer centers in Russia. We assessed efficacy, safety profile of vinflunine in this subset of patients.Results. Clinical efficacy of vinflunine (complete response + partial response + stable disease) was 73.3 %, one patient demonstrated complete response.
more » ... of response duration accounts for 3.8 months. Six-month and 1-year survival rate made up 93.3 %. Adverse events were observed in 53.5 %, with only one episode of neutropenia 4 grade.Conclusion. In our second analysis vinflunine was more effective than in randomized clinical trial and other studies from real practice in Europe. Thus, we confirm expediency to administer of vinflunine for metastatic urothelial carcinoma.
doi:10.17650/1726-9776-2020-16-3-135-142 fatcat:kaob6zvblbesrajoomzi2opvji